Literature DB >> 33176429

The LAIs Are Coming! Implementation Science Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.

John T Kanazawa1, Parya Saberi2, John A Sauceda2, Karine Dubé1.   

Abstract

Long-acting injectable antiretroviral therapy (LAI-ART) is one of the latest advancements in HIV control with the potential to overcome oral ART barriers to adherence. The objective of this article is to anticipate and examine implementation considerations for LAI-ART using components of the PRISM model, a Practical, Robust Implementation and Sustainability Model for integrating research findings into practice. We conducted a scoping review from January to August 2020 of the growing literature on LAI-ART implementation and other fields using LAI therapies. Key considerations regarding LAI-ART were parsed from the searches and entered into the PRISM implementation science framework. The PRISM framework posed multiple questions for consideration in the development of an optimal implementation strategy for LAI-ART in the United States. These questions revealed the necessity for more data, including acceptability of LAI-ART among many different subgroups of people living with HIV (PLWH), cost effectiveness, patient satisfaction, and patient-reported outcomes, as well as more detailed information related to the external environment for optimal LAI-ART implementation. Ethical considerations of LAI-ART will also need to be considered. The anticipation of, and excitement for, LAI-ART represent the hope for a new direction for HIV treatment that reduces adherence barriers and improves prognoses for PLWH. We have a unique window of opportunity to anticipate implementation considerations for LAI-ART, so this new therapy can be used to its fullest potential. Outstanding questions remain, however, that need to be addressed to help achieve HIV suppression goals in diverse populations.

Entities:  

Keywords:  HIV; PRISM framework; antiretroviral therapy; implementation science; injectables; long acting

Mesh:

Year:  2020        PMID: 33176429      PMCID: PMC8020525          DOI: 10.1089/AID.2020.0126

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  101 in total

Review 1.  The population effectiveness of highly active antiretroviral therapy: are good drugs good enough?

Authors:  Thomas P Giordano; Maria E Suarez-Almazor; Richard M Grimes
Journal:  Curr HIV/AIDS Rep       Date:  2005-11       Impact factor: 5.071

2.  Interest of Youth Living With HIV in Long-Acting Antiretrovirals.

Authors:  Ethel D Weld; Md Sohel Rana; Ronald H Dallas; Andres F Camacho-Gonzalez; Patrick Ryscavage; Aditya H Gaur; Rana Chakraborty; Susan Swindells; Charles Flexner; Allison L Agwu
Journal:  J Acquir Immune Defic Syndr       Date:  2019-02-01       Impact factor: 3.731

3.  Prevention of HIV-1 infection with early antiretroviral therapy.

Authors:  Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming
Journal:  N Engl J Med       Date:  2011-07-18       Impact factor: 91.245

4.  Rates and types of psychiatric disorders in perinatally human immunodeficiency virus-infected youth and seroreverters.

Authors:  Claude Ann Mellins; Elizabeth Brackis-Cott; Cheng-Shiun Leu; Katherine S Elkington; Curtis Dolezal; Andrew Wiznia; Mary McKay; Mahrukh Bamji; Elaine J Abrams
Journal:  J Child Psychol Psychiatry       Date:  2009-02-27       Impact factor: 8.982

Review 5.  Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review.

Authors:  Angela A Aidala; Michael G Wilson; Virginia Shubert; David Gogolishvili; Jason Globerman; Sergio Rueda; Anne K Bozack; Maria Caban; Sean B Rourke
Journal:  Am J Public Health       Date:  2015-11-12       Impact factor: 9.308

6.  The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes.

Authors:  Maggie Breslin; Rebecca J Mullan; Victor M Montori
Journal:  Patient Educ Couns       Date:  2008-09-03

7.  Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.

Authors:  Andrea Mantsios; Miranda Murray; Tahilin S Karver; Wendy Davis; David Margolis; Princy Kumar; Susan Swindells; U Fritz Bredeek; Miguel García Del Toro; Mercedes Garcia Gasalla; Rafael Rubio García; Antonio Antela; Krischan Hudson; Sandy Griffith; Deanna Kerrigan
Journal:  AIDS Behav       Date:  2020-05-14

Review 8.  Implantable Polymeric Drug Delivery Devices: Classification, Manufacture, Materials, and Clinical Applications.

Authors:  Sarah A Stewart; Juan Domínguez-Robles; Ryan F Donnelly; Eneko Larrañeta
Journal:  Polymers (Basel)       Date:  2018-12-12       Impact factor: 4.329

Review 9.  Emerging Trends in the Long-Acting Antiretroviral Therapy: Current Status and Therapeutic Challenges.

Authors:  Rajpushpa Labh; Rachna Gupta
Journal:  Curr HIV Res       Date:  2021       Impact factor: 1.581

Review 10.  Improving the Adherence to Antiretroviral Therapy, a Difficult but Essential Task for a Successful HIV Treatment-Clinical Points of View and Practical Considerations.

Authors:  Simona A Iacob; Diana G Iacob; Gheorghita Jugulete
Journal:  Front Pharmacol       Date:  2017-11-23       Impact factor: 5.810

View more
  6 in total

1.  Equity in access to long-acting injectables in the USA.

Authors:  J Carlo Hojilla; Monica Gandhi; Derek D Satre; Mallory O Johnson; Parya Saberi
Journal:  Lancet HIV       Date:  2022-02-04       Impact factor: 12.767

2.  Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.

Authors:  Karine Dubé; John Kanazawa; Lynda Dee; Jeff Taylor; Danielle M Campbell; Brandon Brown; Mallory O Johnson; Parya Saberi; John A Sauceda; Jeremy Sugarman; Michael J Peluso
Journal:  HIV Res Clin Pract       Date:  2021-03-24

3.  Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States.

Authors:  Karine Dubé; John Kanazawa; Lynda Dee; Jeff Taylor; John A Sauceda; Sara Gianella; Davey Smith; Steven G Deeks; Michael J Peluso
Journal:  AIDS Res Ther       Date:  2021-10-18       Impact factor: 2.846

Review 4.  Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV.

Authors:  Morgan M Philbin; Amaya Perez-Brumer
Journal:  Curr Opin HIV AIDS       Date:  2022-03-01       Impact factor: 4.283

5.  Implementation of South Africa's Central Chronic Medicine Dispensing and Distribution Program for HIV Treatment: A Qualitative Evaluation.

Authors:  Laura M Bogart; Zinhle Shazi; Sarah MacCarthy; Alexandra Mendoza-Graf; Nafisa J Wara; Dani Zionts; Nduduzo Dube; Sabina Govere; Ingrid V Bassett
Journal:  AIDS Behav       Date:  2022-02-04

6.  Are Patients and Their Providers Talking About Long-Acting Injectable Antiretroviral Therapy? Penetration into Clinical Encounters at Three U.S. Care Sites.

Authors:  Katerina A Christopoulos; Jonathan Colasanti; Mallory O Johnson; Manami Diaz Tsuzuki; Xavier A Erguera; Rey Flores; Jared Kerman; Kaylin Dance; John A Sauceda; Torsten B Neilands; Samantha E Dilworth; Kimberly A Koester; Jose Gutierrez; John A Schneider; Elizabeth Montgomery; Moira C McNulty
Journal:  Open Forum Infect Dis       Date:  2022-06-11       Impact factor: 4.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.